Suppr超能文献

CD22 是一种再循环受体,可在 B 细胞的细胞表面和内体隔室之间运输货物。

CD22 is a recycling receptor that can shuttle cargo between the cell surface and endosomal compartments of B cells.

机构信息

Department of Chemical Physiology, The Scripps Research Institute, La Jolla, CA 92037, USA.

出版信息

J Immunol. 2011 Feb 1;186(3):1554-63. doi: 10.4049/jimmunol.1003005. Epub 2010 Dec 22.

Abstract

CD22 is a member of the sialic acid-binding Ig-like lectin (Siglec) family that is known to be a regulator of B cell signaling. Its B cell-specific expression makes it an attractive target for immunotoxin-mediated B cell depletion therapy for the treatment of B cell lymphomas and autoimmune diseases. Although CD22 is well documented to be an endocytic receptor, it is believed that after internalization, it is targeted for degradation. We show in this study that CD22 is instead constitutively recycled to the cell surface. We also find that glycan ligand-based cargo is released from CD22 and accumulates intracellularly as CD22 recycles between the cell surface and endosomal compartments. In contrast, Abs to CD22 do not accumulate but remain bound to CD22 and recycle to the cell surface. The results have implications for development of agents that target CD22 as an endocytic receptor for delivery of cytotoxic cargo to B cells.

摘要

CD22 是唾液酸结合免疫球蛋白样凝集素 (Siglec) 家族的成员,已知是 B 细胞信号转导的调节剂。其 B 细胞特异性表达使其成为免疫毒素介导的 B 细胞耗竭治疗 B 细胞淋巴瘤和自身免疫性疾病的有吸引力的靶标。尽管 CD22 被很好地证明是一种内吞受体,但据信它在被内化后被靶向降解。在这项研究中,我们表明 CD22 实际上是不断循环回到细胞表面的。我们还发现,糖基配体基货物从 CD22 释放出来,并在 CD22 在细胞表面和内体隔室之间循环时在细胞内积累。相比之下,针对 CD22 的 Abs 不会积累,而是保持与 CD22 结合并循环回到细胞表面。这些结果对于开发以 CD22 为内吞受体的药物具有重要意义,这些药物可将细胞毒性货物递送至 B 细胞。

相似文献

1
CD22 is a recycling receptor that can shuttle cargo between the cell surface and endosomal compartments of B cells.
J Immunol. 2011 Feb 1;186(3):1554-63. doi: 10.4049/jimmunol.1003005. Epub 2010 Dec 22.
2
CD22 Ligands on a Natural N-Glycan Scaffold Efficiently Deliver Toxins to B-Lymphoma Cells.
J Am Chem Soc. 2017 Sep 13;139(36):12450-12458. doi: 10.1021/jacs.7b03208. Epub 2017 Aug 31.
3
Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22.
Leuk Lymphoma. 2012 Feb;53(2):208-10. doi: 10.3109/10428194.2011.604755. Epub 2011 Aug 24.
4
In vivo targeting of B-cell lymphoma with glycan ligands of CD22.
Blood. 2010 Jun 10;115(23):4778-86. doi: 10.1182/blood-2009-12-257386. Epub 2010 Feb 24.
5
Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity.
Mol Cell Biol. 2007 Aug;27(16):5699-710. doi: 10.1128/MCB.00383-07. Epub 2007 Jun 11.
8
In situ trans ligands of CD22 identified by glycan-protein photocross-linking-enabled proteomics.
Mol Cell Proteomics. 2010 Jun;9(6):1339-51. doi: 10.1074/mcp.M900461-MCP200. Epub 2010 Feb 19.
9
Murine Red Blood Cells Lack Ligands for B Cell Siglecs, Allowing Strong Activation by Erythrocyte Surface Antigens.
J Immunol. 2018 Feb 1;200(3):949-956. doi: 10.4049/jimmunol.1701257. Epub 2017 Dec 29.
10
Targeting of CD22-positive B-cell lymphoma cells by synthetic divalent sialic acid analogues.
Eur J Immunol. 2012 Oct;42(10):2792-802. doi: 10.1002/eji.201242574. Epub 2012 Aug 6.

引用本文的文献

1
A versatile antibody capture system drives specific in vivo delivery of mRNA-loaded lipid nanoparticles.
Nat Nanotechnol. 2025 Sep;20(9):1273-1284. doi: 10.1038/s41565-025-01954-9. Epub 2025 Aug 4.
2
M2-Like Macrophages Exhibit Sialic Acid-Enhanced Efferocytosis via the Siglec CD22.
FASEB J. 2025 Jul 15;39(13):e70767. doi: 10.1096/fj.202500146RR.
3
Rational design of FVIII sialylated peptides to target Siglec-3 and Siglec-9 and improve peptide formulations for reverse vaccines.
Front Bioeng Biotechnol. 2025 Apr 10;13:1558627. doi: 10.3389/fbioe.2025.1558627. eCollection 2025.
4
CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses.
Sci Adv. 2025 Apr 11;11(15):eadq4297. doi: 10.1126/sciadv.adq4297. Epub 2025 Apr 9.
5
Immune-related adverse events of antibody-based biological medicines in cancer therapy.
J Cell Mol Med. 2024 Jul;28(13):e18470. doi: 10.1111/jcmm.18470.
6
A high-throughput lysosome trafficking assay guides ligand selection and elucidates differences in CD22-targeted nanodelivery.
Sci Technol Adv Mater. 2024 May 13;25(1):2351791. doi: 10.1080/14686996.2024.2351791. eCollection 2024.
8
Sialic acid in the regulation of blood cell production, differentiation and turnover.
Immunology. 2024 Aug;172(4):517-532. doi: 10.1111/imm.13780. Epub 2024 Mar 19.
9
Siglec-15/sialic acid axis as a central glyco-immune checkpoint in breast cancer bone metastasis.
Proc Natl Acad Sci U S A. 2024 Jan 30;121(5):e2312929121. doi: 10.1073/pnas.2312929121. Epub 2024 Jan 22.
10
Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design.
Front Immunol. 2023 Nov 27;14:1294929. doi: 10.3389/fimmu.2023.1294929. eCollection 2023.

本文引用的文献

2
In vivo targeting of B-cell lymphoma with glycan ligands of CD22.
Blood. 2010 Jun 10;115(23):4778-86. doi: 10.1182/blood-2009-12-257386. Epub 2010 Feb 24.
3
In situ trans ligands of CD22 identified by glycan-protein photocross-linking-enabled proteomics.
Mol Cell Proteomics. 2010 Jun;9(6):1339-51. doi: 10.1074/mcp.M900461-MCP200. Epub 2010 Feb 19.
4
Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression.
Br J Haematol. 2010 Jan;148(1):99-109. doi: 10.1111/j.1365-2141.2009.07939.x. Epub 2009 Oct 11.
5
Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.
J Clin Oncol. 2009 Jun 20;27(18):2983-90. doi: 10.1200/JCO.2008.20.2630. Epub 2009 May 4.
6
Siglecs as targets for therapy in immune-cell-mediated disease.
Trends Pharmacol Sci. 2009 May;30(5):240-8. doi: 10.1016/j.tips.2009.02.005. Epub 2009 Apr 7.
7
Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection.
Cancer Res. 2009 Mar 15;69(6):2358-64. doi: 10.1158/0008-5472.CAN-08-2250. Epub 2009 Mar 3.
9
Siglecs as positive and negative regulators of the immune system.
Biochem Soc Trans. 2008 Dec;36(Pt 6):1467-71. doi: 10.1042/BST0361467.
10
An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes.
Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11311-6. doi: 10.1073/pnas.0804851105. Epub 2008 Aug 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验